**Chapter 8**

*Advances in Hematologic Malignancies*

[60] Gada P, Hernandez-Ilizalituri FJ, Repasky EA, et al. Epratuzumab's predominant anti-tumor activity in vitro/in vivo against non-Hodgkin's lymphoma (NHL) is via antibodydependent cellular cytotoxicity (ADCC). Blood. 2002;**100**:1367a

[61] Karlin L, Coiffier B. Ofatumumab in the treatment of non-Hodgkin's lymphomas. Expert Opinion on

[62] Marcus R, Davies A, Ando K, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. The New England Journal of Medicine. 2017;**377**:1331-1344. DOI: 10.1056/

[63] Schmidt M, Finley D. Regulation of proteasome activity in health and disease. Biochimica et Biophysica Acta. 2014;**1843**:13-25. DOI: 10.1016/j.

[64] Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. Journal of Clinical Oncology. 2002;**20**:4420-4427. DOI:

Epub 2015 Jun 4

NEJMoa1614598

bbamcr.2013.08.012

10.1200/JCO.2002.01.133

10.1056/NEJMoa030288

oncotarget.25281

[65] Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. The New England Journal of Medicine. 2003;**348**:2609-2617. DOI:

[66] Shah C, Bishnoi R, Wang Y, et al. Efficacy and safety of carfilzomib in relapsed and/o refractory multiple myeloma: Systematic review and meta-analysis of 14 trials. Oncotarget. 2018;**9**:23704-23717. DOI: 10.18632/

Biological Therapy. 2015;**15**(7):1085-1091. DOI: 10.1517/14712598.2015.1055241.

monoclonal antibody, LL2. International Journal of Cancer. 1994;**56**:538-545

[67] Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor in relapsed/refractory multiple myeloma patients. Blood. 2014;**124**:1038-1046. DOI: 10.1182/blood-2014-01-548826

[68] Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus Bortezomib, Melphalan, and prednisone for untreated myeloma. The New England Journal of Medicine. 2018;**378**:518-528. DOI: 10.1056/

[69] Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. The New England Journal of Medicine. 2015;**373**:621-631. DOI:

NEJMoa1714678

10.1056/NEJMoa1505654

**136**
